Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

Key Points

• To correct specific data points related to clinical remission rates in ulcerative colitis.
• Correction of numerical values reported in results
• Revising clinical remission percentages based on updated data
• Updated clinical remission rate is 27.3% (15/55) instead of 33.3% (15/45)
• Clarified data improves understanding of treatment efficacy